Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Moss – page 4

130 clinical trials in Moss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Moss at a glance
130
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

130 trials in Moss

Open in trial search

Study on the Effects of ILB and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Riluzole
  • Sponsor:Oslo University Hospital HF

Study on the Effectiveness of Tenecteplase in Patients with Acute Ischemic Stroke Taking Rivaroxaban, Apixaban, or Edoxaban

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Oslo University Hospital HF

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Rituximab, Lenalidomide, and Tafasitamab for Treating High-Risk and Low-Risk Follicular Lymphoma Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Karolinska University Hospital

Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib
  • Sponsor:Oslo University Hospital HF

Back pain

Recruiting

Study on Zoledronic Acid for Patients with Chronic Low Back Pain with Modic Changes

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Oslo University Hospital HF

Pneumonia

Recruiting

Study on the Effect of Amoxicillin in Preschool Children with Pneumonia

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Amoxicillin Trihydrate
  • Sponsor:Oslo University Hospital HF

Study on Mitomycin and BCG for Patients with Recurrent Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Aarhus University

Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Oslo University Hospital HF

Study on Treatment Strategies for Children and Adolescents with Juvenile Idiopathic Arthritis Using Methotrexate and Drug Combination

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Oslo University Hospital HF

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Hamilton Health Sciences Corporation

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Moss

What the registry says about research in the country

01 Rheumatology & Immunology

Clinical research focusing on giant cell arteritis (GCA), exploring innovative therapeutic approaches for this rare inflammatory blood vessel condition. The trials aim to evaluate new treatment combinations that could improve patient outcomes while optimizing glucocorticoid therapy regimens.

  • Inflammatory Vascular Disorders
  • Autoimmune Disease Management
  • Targeted Immunotherapy

These investigations are designed to assess the effectiveness of combining novel biological treatments with traditional steroid therapies, potentially offering new hope for patients managing chronic inflammatory conditions.

02 Therapeutic Innovation

Advanced studies evaluating combination therapy approaches that integrate biological agents with standardized glucocorticoid tapering protocols. This research aims to establish more effective treatment strategies while potentially reducing long-term steroid exposure.

  • Treatment Optimization
  • Steroid-Sparing Strategies
  • Long-term Disease Management

The research focuses on developing sustained remission protocols that could revolutionize the standard of care for inflammatory vascular conditions.

03 Clinical Outcomes

Comprehensive evaluation of treatment efficacy and safety in vascular inflammation, with particular attention to sustained disease remission. The research examines both immediate therapeutic responses and long-term outcomes in patients with inflammatory arterial disease.

  • Remission Assessment
  • Safety Monitoring
  • Quality of Life Impacts

These trials are designed to provide crucial data on the effectiveness of new therapeutic approaches in achieving and maintaining disease control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.